NS
Highly rated in
9
conditions
Highly rated in
9
conditions
Check Dr. Nirmish R. Shah's experience treating your condition:
About Dr. Nirmish R. Shah

Nirmish Shah is a Hematologist Oncology specialist and a Pediatrics expert in Durham, North Carolina. Shah has been practicing medicine for over 23 years and is highly rated in 9 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant. He is licensed to treat patients in North Carolina. Shah is currently accepting new patients.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 16 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Nirmish R. Shah it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Nirmish R. Shah accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Bright Health
  •  Cigna
  •  UnitedHealthcare
  •  Aetna

Call to see if your plan is accepted.
Locations
40 Duke Medicine Cir, Durham, NC 27710
Background & Education
Graduate Institution
Other, 2000
Specialties
Hematology Oncology
Pediatrics
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Arabic
Spanish
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


16 Clinical Trials

Patient-Empowered Mobile Technology in Hospitalized Patients: Technology Resources to Understand Pain Assessment in Patients With Pain (TRU-PAIN)
A Phase 1/2, Open-Label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB1 in Adult Patients With Sickle Cell Disease (SCD)
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization- mESH Study
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study.
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Role of Virtual Reality (VR) in Decreasing Pain and Anxiety in Patients With Sickle Cell Disease (SCD)
Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease
Use of a Mobile-based Pain Assessment Application for SCD Patients
Use of Mobile Technology for Intensive Training in Medication Management
View 12 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors